
Dr. Nitin Singhal is a leading onco-surgeon in Ahmedabad, specializing in the diagnosis, surgical treatment, and management of urinary bladder cancer.
With over 15 years of experience in surgical oncology, he is recognized for his expertise in robotic surgery, minimally invasive techniques, and HIPEC, offering patients advanced, patient-focused cancer care.
Bladder cancer develops in the cells of the urinary bladder, the organ responsible for storing urine. It is one of the most common urological cancers, particularly in men over the age of 50.
The majority of bladder cancers are urothelial carcinomas, also called transitional cell carcinomas. Less common types include squamous cell carcinoma and adenocarcinoma.
Early symptoms can include blood in the urine (hematuria), frequent urination, burning or pain during urination, and pelvic discomfort. Because some symptoms can resemble urinary infections, timely medical evaluation is important when symptoms persist or recur.
Treatment depends on the type and stage of bladder cancer. Depending on the individual case, management may involve TURBT, intravesical treatment, partial or radical cystectomy, chemotherapy, radiation therapy, or other multidisciplinary treatment approaches.
Bladder cancer may present with urinary symptoms that can sometimes be mistaken for an infection. Persistent or unexplained urinary changes should be medically evaluated.
Blood in the urine should not be ignored, even when it occurs without significant pain.
Some bladder cancer symptoms can resemble a urinary infection. If urinary symptoms persist, return repeatedly, or do not improve as expected, specialist evaluation can help determine the underlying cause.
Early evaluation can help identify bladder cancer at a stage when treatment options may be broader.
Bladder cancer can develop from different types of cells, with urothelial carcinoma being the most common form.
Urothelial carcinoma, also known as transitional cell carcinoma, is the most common type of bladder cancer. It develops in the cells lining the urinary tract.
Squamous cell carcinoma is a less common type of bladder cancer. Its treatment depends on the extent and characteristics of the disease.
Adenocarcinoma is another uncommon bladder cancer type. Specialist evaluation is required to determine the appropriate treatment strategy.
Dr. Nitin Singhal offers comprehensive bladder cancer treatment in Ahmedabad, with treatment tailored to the type, stage, and extent of the cancer.
Depending on the individual case, treatment may involve surgery, intravesical therapy, systemic treatment, radiation therapy, or a combination of approaches.
The stage of bladder cancer helps determine how deeply the tumour has invaded the bladder and whether it has spread beyond the bladder.
At this stage, abnormal cancer cells are limited to the innermost lining of the bladder and have not invaded deeper layers. These tumours are generally considered non-muscle invasive. Treatment commonly involves TURBT, followed when appropriate by intravesical therapy and regular follow-up.
Stage I bladder cancer has grown into the connective tissue beneath the bladder lining but has not invaded the muscle layer. It is classified as non-muscle invasive bladder cancer. TURBT followed by appropriate intravesical treatment and regular cystoscopic surveillance may be used.
At Stage II, the cancer has invaded the muscular wall of the bladder. This is known as muscle-invasive bladder cancer. Treatment may involve radical cystectomy with urinary diversion or, in selected cases, a bladder-preserving approach using chemotherapy and radiation.
Stage III bladder cancer has extended beyond the bladder muscle into surrounding tissues or nearby structures and may involve regional lymph nodes. Treatment generally requires a multidisciplinary approach and may include surgery, systemic chemotherapy, and radiation depending on the extent of disease.
Stage IV represents the most advanced disease, where bladder cancer may involve more distant lymph nodes or distant organs such as the lungs, liver, or bones. Treatment focuses on controlling the disease, managing symptoms, and maintaining quality of life through appropriate systemic and supportive therapies.
In selected patients, bladder preservation may be considered depending on the stage, location, extent, and characteristics of the tumour.
Depending on the clinical situation, a bladder-preserving strategy may involve tumour resection followed by chemotherapy and radiation. The suitability of this approach must be assessed individually by the treating cancer team.
Dr. Nitin Singhal specialises in robotic and minimally invasive cancer surgery. When appropriate for the patient's condition, these techniques can provide precise surgical access while reducing the need for large incisions.
The choice between open, laparoscopic, and robotic surgery depends on the cancer, the required procedure, the patient's condition, and the surgeon's assessment.
Common questions about symptoms, diagnosis, treatment, surgery, and bladder preservation.
Blood in the urine, also called hematuria, is one of the most important warning signs. Other symptoms can include frequent urination, burning or pain during urination, and pelvic discomfort. Because these symptoms can resemble urinary infections, persistent or recurring symptoms should be evaluated by a doctor.
No. Blood in the urine can occur for several different reasons. However, unexplained blood in the urine should not be ignored. A specialist evaluation can help determine the underlying cause and whether further investigation is required.
TURBT stands for Transurethral Resection of Bladder Tumor. It is a commonly used procedure for early-stage bladder tumours in which the tumour is removed through the urethra using a specialised instrument, avoiding the need for an abdominal incision.
No. Many early bladder cancers are treated without removing the entire bladder. TURBT and intravesical therapy may be used for appropriate non-muscle invasive disease. In selected muscle-invasive cases, chemotherapy combined with radiation may also be considered as a bladder-preserving approach.
Radical cystectomy is a major surgical procedure in which the urinary bladder is removed. It may be recommended for selected muscle-invasive or advanced bladder cancers. Because urine must still leave the body after bladder removal, urinary diversion or reconstruction may be required.
BCG is an intravesical immunotherapy used for selected bladder cancers, particularly certain non-muscle invasive tumours. It is delivered directly into the bladder rather than given systemically.
Robotic surgery can provide a minimally invasive approach for selected bladder cancer procedures. Its suitability depends on the cancer stage, required operation, patient's health, and surgeon's assessment. Robotic techniques are designed to provide precision while potentially reducing blood loss and supporting recovery.
Bladder cancer can recur, particularly in non-muscle invasive disease. This is why regular follow-up and appropriate surveillance are important after treatment. The follow-up schedule depends on the type and stage of cancer and the treatment received.
The outlook depends on the type, stage, extent of spread, and response to treatment. Early bladder cancer can often be treated effectively, while advanced disease may require a combination of surgery and systemic treatments. A specialist evaluation is necessary to understand the expected treatment approach for an individual patient.
If you have noticed blood in your urine, persistent urinary symptoms, or have already been diagnosed with bladder cancer, consult an experienced cancer specialist for appropriate evaluation and personalised treatment planning.
Dr. Nitin Singhal has been recognised for his contribution to cancer care and surgical oncology, reflecting his commitment to advanced surgical techniques, clinical excellence and patient-centred care.
Surgical oncology training from Tata Memorial Hospital, Mumbai.
Expertise across complex and multidisciplinary cancer surgery.
Honoured for excellence in healthcare and surgical oncology.
Focus on evidence-based and personalised cancer treatment.
Recognition that reflects a continued commitment to excellence in cancer care.